Is Leishmaniasis Threatening Your Dog? What You Need to Know
"Uncover the facts about Leishmania infection in dogs and how to protect your furry friend from this emerging threat in unexpected locations."
For decades, American visceral leishmaniasis (AVL) was a disease largely confined to specific regions. However, the landscape is changing, with new cases emerging in areas previously considered low-risk. This shift means that dog owners everywhere need to be more aware of the risks and how to protect their beloved pets.
Once heavily concentrated in the northeast of Brazil, AVL has expanded its reach, now significantly impacting the southeast. This territorial expansion highlights the adaptive capacity of the vectors that transmit the disease, making it a concern even in urban centers.
A recent study focused on Florianópolis, Santa Catarina, Brazil, a region initially considered free of visceral leishmaniasis, until autochthonous cases were reported in 2011. The research highlights the importance of understanding the occurrence and spread of Leishmania in canine populations, and underscores why dog owners need to stay informed.
Guidelines and Diagnostic Challenges
Consensus guidelines offer evidence-based approaches to diagnosing, treating, and preventing canine leishmaniosis, but veterinarians do not always follow scientifically sound methods. Infection may become patent within 1–2 months in some dogs, while other infections remain sub-patent for more than a year. A few dogs may test PCR-negative for several months before infection re-emerges and progresses, illustrating a challenge for detection and follow-up.
What are the key findings from the Florianópolis study?
The study, conducted in Florianópolis, examined 491 dogs to assess the prevalence of Leishmania infection. Researchers used two serological methods, ELISA and IFAT, to detect antibodies against Leishmania sp. The results indicated a seroprevalence of 0.4% by ELISA and 4.09% by IFAT. In total, 5.3% of the dogs tested positive for Leishmania infection.
- ELISA: 0.4% (2/491)
- IFAT: 4.09% (24/491)
- Total Seroreactivity: 5.3% (25/491)
A 2025 Study of Prognosis
A study published November 18, 2025, describes canine leishmaniosis caused by Leishmania infantum as ranging from subclinical infection to systemic, chronic, and potentially fatal disease. The study aimed to identify risk factors for poor prognosis in affected dogs, focusing on demographic and epidemiological factors. Its summary says treatment response is influenced by host, vector, and environmental factors, but does not specify the study’s findings.
The Reservoir and Disease Burden
A 2022 review identifies dogs as the main reservoir of Leishmania infantum and describes canine leishmaniasis as an incurable multisystemic disease. It reports that the disease leads to death in symptomatic dogs when untreated. The parasite also causes visceral, cutaneous, and mucosal leishmaniasis in people in the Mediterranean Basin, North Africa, South America, and West Asia.
A One Health Perspective
An article on clinical management of canine leishmaniosis versus human leishmaniasis invokes the One Health initiative. The initiative seeks to rapidly detect emerging or re-emerging infectious diseases in humans and animals. The article identifies deforestation, some agricultural practices, and the appearance of new foci of Leishmania infantum with alternative reservoirs as epidemiological situations it aims to help prevent.
What Does This Mean for Dog Owners?
The emergence of leishmaniasis in new regions underscores the need for heightened awareness and proactive measures. Dog owners should consult with their veterinarians about regular screening, especially if living in or traveling to areas where the disease has been reported. Preventive measures, such as using insect repellents effective against sandflies (the vectors of Leishmania) and avoiding outdoor activities during peak sandfly hours, can also help reduce the risk of infection.
Diagnosis and Public Health
A 2022 update reports that canine leishmaniasis diagnosis has evolved through analysis of new samples using novel molecular techniques. It also describes the implications of the disease’s epidemiology, diagnosis, treatment, and prevention as fundamental to public health. The source summary does not name the techniques or provide specific performance data.
Forecasting Future Incidence
A 2026 forecasting study compiled long-term positivity trends and compared them with regional temperature records from the Servei Meteorològic de Catalunya. To forecast future incidence, it adapted an existing single-season SEIRD model of human leishmaniasis into a multiseason, dual-host system involving dogs and sandflies. The source describes this modeling approach but does not provide forecast results in the supplied summary.